Reduction of no-reflow and reperfusion injury with the synthetic 17β-aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade

被引:53
作者
Hernandez-Resendiz, Sauri [1 ]
Palma-Flores, Carlos [2 ]
De los Santos, Sergio [2 ]
Roman-Anguiano, Nadia G. [1 ]
Flores, Mirthala [3 ]
de la Pena, Aurora [3 ,4 ]
Flores, Pedro L. [5 ]
Fernandez-G, Juan M. [6 ]
Coral-Vazquez, Ramon M. [2 ,7 ]
Zazueta, Cecilia [1 ]
机构
[1] Inst Nacl Cardiol, Dept Biomed Cardiovasc, Mexico City 14080, DF, Mexico
[2] Inst Seguridad & Serv Sociales Trabajadores Estad, Ctr Med Nacl Noviembre 20, Subdirecc Ensenanza Invest, Mexico City 03100, DF, Mexico
[3] Inst Nacl Cardiol, Dept Biol Mol, Mexico City 14080, DF, Mexico
[4] Univ Nacl Autonoma Mexico, Fac Med, Dept Farmacol, Mexico City 04510, DF, Mexico
[5] Inst Nacl Cardiol, Dept Instrumentac Electromecan, Mexico City 14080, DF, Mexico
[6] Univ Nacl Autonoma Mexico, Inst Quim, Circuito Exterior, Mexico City 04510, DF, Mexico
[7] Inst Politecn Nacl, Escuela Super Med, Secc Estudios Posgrad & Invest, Mexico City 11340, DF, Mexico
关键词
Myocardial infarction; Reperfusion injury; No-reflow; Prolame; Cardioprotection; Nitric oxide; ACUTE MYOCARDIAL-INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; NITRIC-OXIDE SYNTHASE; VASCULAR SMOOTH-MUSCLE; ISCHEMIA-REPERFUSION; THROMBOLYTIC THERAPY; PRIMARY ANGIOPLASTY; CONTROLLED-TRIAL; ADENOSINE; ESTROGEN;
D O I
10.1007/s00395-015-0464-y
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
A high proportion of primary percutaneous coronary interventions performed in the setting of acute myocardial infarction, concur with inadequate myocardial perfusion at the microvascular level. This phenomenon, known as "no-reflow'' contributes to reperfusion injury, poor prognosis and to unfavorable clinical outcome. In this study, we evaluated the hypothesis that the synthetic 17 beta-aminoestrogen Prolame, may confer cardioprotection and prevent against no-reflow. In an open-chest model of 30-min ischemia and 90-min reperfusion, male Wistar rats were randomly assigned to different groups: Control, Prolame, Prolame followed by the nitric oxide synthase inhibitor (L-NAME), and 17 beta-estradiol. Areas of risk, infarct size and no-reflow were determined by planimetry with triphenyltetrazolium chloride and thioflavin-S stains. Structural damage of the vasculature was measured as capillary compression in clarified tissue after intra-atrial injection of Microfil. Hemodynamic function was obtained at the end of stabilization, ischemia and reperfusion; nitric oxide (NO center dot) content was determined indirectly using the Griess reaction. Activation of the eNOS signaling cascade was determined by western blot. Prolame reduced the infarcted area, decreased the zones of no-reflow and capillary compression by activating the PI3K/Akt/eNOS signaling pathway in correlation with NO center dot increase. Prolame also activated endothelial cells augmenting NO center dot production, which was inhibited by ICI182780 (a selective estrogen receptor down-regulator), supporting the notion that the cardioprotective effect of Prolame involves the preservation of endothelium through the activation of estrogen receptor downstream signaling. Our results provide evidence that Prolame has potential therapeutic application in patients with AMI, as it prevents from both vascular and cardiac tissue damage.
引用
收藏
页数:12
相关论文
共 52 条
[1]
Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial [J].
Amit, Guy ;
Cafri, Carlos ;
Yaroslavtsev, Sergei ;
Fuchs, Shmuel ;
Paltiel, Ora ;
Abu-Ful, Akram ;
Weinstein, Jean M. ;
Wolak, Arik ;
Ilia, Reuben ;
Zahger, Doran .
AMERICAN HEART JOURNAL, 2006, 152 (05) :887.e9-887.e14
[2]
APPARENT HYDROXYL RADICAL PRODUCTION BY PEROXYNITRITE - IMPLICATIONS FOR ENDOTHELIAL INJURY FROM NITRIC-OXIDE AND SUPEROXIDE [J].
BECKMAN, JS ;
BECKMAN, TW ;
CHEN, J ;
MARSHALL, PA ;
FREEMAN, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (04) :1620-1624
[3]
NITRIC-OXIDE ATTENUATES CARDIAC MYOCYTE CONTRACTION [J].
BRADY, AJB ;
WARREN, JB ;
POOLEWILSON, PA ;
WILLIAMS, TJ ;
HARDING, SE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (01) :H176-H182
[4]
Management of the no-reflow phenomenon [J].
Butler, Michelle J. ;
Chan, William ;
Taylor, Andrew J. ;
Dart, Anthony M. ;
Duffy, Stephen J. .
PHARMACOLOGY & THERAPEUTICS, 2011, 132 (01) :72-85
[5]
Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy [J].
Coral-Vazquez, R ;
Cohn, RD ;
Moore, SA ;
Hill, JA ;
Weiss, RM ;
Davisson, RL ;
Straub, V ;
Barresi, R ;
Bansal, D ;
Hrstka, RF ;
Williamson, R ;
Campbell, KP .
CELL, 1999, 98 (04) :465-474
[6]
Fernandez-G JM, 1985, STEROIDS, V45, P151
[7]
Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation [J].
Florian, M ;
Lu, Y ;
Angle, M ;
Magder, S .
STEROIDS, 2004, 69 (10) :637-645
[8]
Effect of High-Dose Intracoronary Adenosine Administration During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction A Randomized Controlled Trial [J].
Fokkema, Marieke L. ;
Vlaar, Pieter J. ;
Vogelzang, Mathijs ;
Gu, Youlan L. ;
Kampinga, Marthe A. ;
de Smet, Bart J. ;
Jessurun, Gillian A. ;
Anthonio, Rutger L. ;
van den Heuvel, Ad F. ;
Tan, Eng-Shiong ;
Zijlstra, Felix .
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (04) :323-329
[9]
Fugit MD, 2000, J INVASIVE CARDIOL, V12, P80
[10]
No-Reflow Phenomenon: Pathophysiology, Diagnosis, Prevention, and Treatment. A Review of the Current Literature and Future Perspectives [J].
Galasso, Gennaro ;
Schiekofer, Stephan ;
D'Anna, Carolina ;
Di Gioia, Giuseppe ;
Piccolo, Raffaele ;
Niglio, Tullio ;
De Rosa, Roberta ;
Strisciuglio, Teresa ;
Cirillo, Plinio ;
Piscione, Federico ;
Trimarco, Bruno .
ANGIOLOGY, 2014, 65 (03) :180-189